×
About 1,433 results

ALLMedicine™ Zollinger-Ellison Syndrome Center

Research & Reviews  88 results

Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zol...
https://doi.org/10.1016/j.pan.2020.12.002
Pancreatology : Official Journal of the International Ass... Perrier M, Delemer B et. al.

Dec 15th, 2020 - We report here the first case of life-threatening hypomagnesemia in a Zollinger-Ellison syndrome patient with multiple endocrine neoplasia type 1 (MEN1) syndrome. The severe symptomatic hypomagnesemia proved to be due to proton pump inhibitors (PP...

Primary intracardiac gastrinoma causing Zollinger-Ellison syndrome.
https://doi.org/10.1093/eurheartj/ehaa512
European Heart Journal; Luiso D, Zuccarino F et. al.

Jul 18th, 2020 - Primary intracardiac gastrinoma causing Zollinger-Ellison syndrome.|2020|Luiso D,Zuccarino F,Tizón-Marcos H,Ble M,|

Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome
https://clinicaltrials.gov/ct2/show/NCT00001254

Apr 20th, 2020 - This protocol concerns the approach to the localization and management of the tumor in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor and the subsequent management of the tumor.

Jejunal Perforations in Zollinger-Ellison Syndrome: Expect the Unexpected.
https://www.ncbi.nlm.nih.gov/pubmed/32106911
The American Surgeon; Freund MR, Reissman P et. al.

Feb 29th, 2020 - Jejunal Perforations in Zollinger-Ellison Syndrome: Expect the Unexpected.|2020|Freund MR,Reissman P,Schwarz AD,|etiology,etiology,etiology,complications,

Manifestation of Zollinger-Ellison Syndrome With Hypovolemic Shock.
https://doi.org/10.1016/j.amjmed.2019.12.037
The American Journal of Medicine; Reisinger AC, Eller P et. al.

Feb 23rd, 2020 - Manifestation of Zollinger-Ellison Syndrome With Hypovolemic Shock.|2020|Reisinger AC,Eller P,Schilcher G,Eisner F,Kreuzer P,|therapeutic use,therapeutic use,etiology,therapy,complications,diagnosis,therapy,

see more →

Drugs  452 results see all →

Clinicaltrials.gov  11 results

Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome
https://clinicaltrials.gov/ct2/show/NCT00001254

Apr 20th, 2020 - This protocol concerns the approach to the localization and management of the tumor in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor and the subsequent management of the tumor.

YF476 and Type II Gastric Carcinoids
https://clinicaltrials.gov/ct2/show/NCT02454075

Aug 19th, 2019 - This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.

Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients
https://clinicaltrials.gov/ct2/show/NCT01753024

Sep 6th, 2018 - Critically ill patients who is able to receive early enteral nutrition and estimated to stay in ICU at least four days are considered to enroll into this study. Exclusion criteria are age under 18 or over 80 years, pregnancy or breastfeeding, know...

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
https://clinicaltrials.gov/ct2/show/NCT00001191

Jul 2nd, 2017 - Patients with Zollinger-Ellison syndrome require continuous control of their gastric acid secretion or else severe complications of peptic ulcer disease will occur. This study investigates the long-term efficacy of the oral gastric acid antisecret...

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer
https://clinicaltrials.gov/ct2/show/NCT00001228

Jul 2nd, 2017 - Heretofore morbidity and mortality in Zollinger-Ellison syndrome were caused by severe ulcer disease. The advent of specific drugs to cure ulcer disease now extends life until metastases from the non-B-islet cell tumor or other events cause death....

see more →

News  18 results

Appco Pharma LLC Issues Voluntary Nationwide Recall of Ranitidine Hydrochloride Capsules 150 mg and 300 mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/appco-pharma-llc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-capsules-150-mg-and-300

Summary Company Announcement Date: January 07, 2020 FDA Publish Date: January 07, 2020 Product Type: Drugs Reason for Announcement: Recall Reason Description NDMA (Nitrosodimethylamine) impurity Company Name: Appco Pharma LLC Brand Name: Brand Nam...

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Pantoprazole Sodium for Injection 40 Mg Per Vial, Due to Presence of Glass Particles in the Vial | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/auromedics-pharma-llc-issues-voluntary-nationwide-recall-pantoprazole-sodium-injection-40-mg-vial

Summary Company Announcement Date: December 19, 2017 FDA Publish Date: December 29, 2017 Product Type: Drugs Generic Drugs Reason for Announcement: Recall Reason Description Contains glass particles Company Name: AuroMedics Pharma LLC Brand Name: ...

Continue, Stop, or Taper the PPI?
https://www.medscape.com/viewarticle/920314_2

Oct 25th, 2019 - My Take: It's Time for a Change. Do You Agree? The patient may not like it, but it's worth at least trying to taper his PPI at this time, with a goal of stopping regular PPI dosing altogether. Like many others, this patient is using his PPI as chr...

Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to An Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-elevated

Summary Company Announcement Date: September 23, 2019 FDA Publish Date: September 23, 2019 Product Type: Drugs Reason for Announcement: Recall Reason Description Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) Compa...

Improper Proton Pump Inhibitor Prescriptions Criticized
https://www.staging.medscape.com/viewarticle/913377

May 22nd, 2019 - SAN DIEGO — Prescriptions for proton pump inhibitors (PPIs) have skyrocketed over the past 2 decades, along with concerns about inappropriate use and adverse events. Prescriptions for PPIs went from 1.6% of ambulatory care visits in 1998 to 7.6% i...

see more →

Patient Education  4 results see all →